

**RUBRA MEDICAMENTS LIMITED**

**Part I**

**(Rupees in Lacs)**

**Statement of Standalone Audited Financial Results for the Quarter and Year Ended March 31, 2017**

Sr. No	Particulars	3 months ended	Preceeding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Pervious year Ended
		31-Mar-2017	31-Dec-2016	31-Mar-2016	31-Mar-2017	31-Mar-2016
		Unaudited	Unaudited	Unaudited	Audited	Audited
1	Income from operations					
	Net Sales/Income form Operations (Net of Excise Duty)	5.74	9.75	6.95	30.62	19.54
	Other Operating Income	0.25	0.00	0.00	0.25	0.00
	<b>Total Income from Operations (Net)</b>	<b>5.99</b>	<b>9.75</b>	<b>6.95</b>	<b>30.87</b>	<b>19.54</b>
2	<b>Expenses</b>					
a	Cost of Materials Consumed	0.00	0.00	0.00	0.00	0.00
b	Purchases of Stock-in-trade	0.00	4.20	5.45	12.13	12.59
c	Changes in Inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00
d	Employee Benefit Expense	0.70	0.40	0.45	2.00	1.80
e	Depreciation and amortisation expenses	0.01	0.01	0.00	0.03	0.00
f	Other Expenses (Any item exceeding 10% of the total expenses relating to continuing operators to be shown separately)	4.42	4.10	0.78	13.31	5.83
	<b>Total Expenses</b>	<b>5.13</b>	<b>8.71</b>	<b>6.68</b>	<b>27.47</b>	<b>20.22</b>
3	<b>Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>0.86</b>	<b>1.04</b>	<b>0.27</b>	<b>3.40</b>	<b>-0.68</b>
4	Other Income	0.00	0.00	0.00	0.00	0.00
5	<b>Profit / (Loss) from Ordinary activities before finance costs and exceptional items (3+4)</b>	<b>0.86</b>	<b>1.04</b>	<b>0.27</b>	<b>3.40</b>	<b>-0.68</b>
6	Finance Cost	0.01	0.00	0.00	0.01	0.00
7	<b>Profit / (Loss) from Ordinary activities after finance costs but before exceptional items (5+6)</b>	<b>0.85</b>	<b>1.04</b>	<b>0.27</b>	<b>3.39</b>	<b>-0.68</b>
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00
9	<b>Profit / (Loss) from Ordinary activities before tax (7+8)</b>	<b>0.85</b>	<b>1.04</b>	<b>0.27</b>	<b>3.39</b>	<b>-0.68</b>
10	Tax Expenses	0.00	0.00	0.00	0.00	0.00
11	<b>Profit / (Loss) from Ordinary activities after tax (9+10)</b>	<b>0.85</b>	<b>1.04</b>	<b>0.27</b>	<b>3.39</b>	<b>-0.68</b>
12	Extraordinary Items (net of tax expense)	0.00	0.00	0.00	0.00	0.00
13	<b>Net Profit / (Loss) for the period (11+12)</b>	<b>0.85</b>	<b>1.04</b>	<b>0.27</b>	<b>3.39</b>	<b>-0.68</b>
14	Share of Profit/(Loss) of associates	0.00	0.00	0.00	0.00	0.00
15	Minority Interest	0.00	0.00	0.00	0.00	0.00
16	<b>Net Profit / (Loss) after taxes, minority interest and share of profit /(loss) of associates (13+14+15)</b>	<b>0.85</b>	<b>1.04</b>	<b>0.27</b>	<b>3.39</b>	<b>-0.68</b>
17	Paid-up equity share capital (Face value of the Share is Rs.10/- each)	546.83	546.83	546.83	546.83	546.83
18	Reserves excluding Revaluation Reserves as per balance sheet) of previous accounting year				-505.03	-508.43
19.i	Earnings Per Share (EPS) (before Extraordinary items) of Rs. 10/- each (not to be annualized)					
	a) Basic	0.02	0.02	0.00	0.06	-0.01
	b) Diluted	0.02	0.02	0.00	0.06	-0.01
19.ii	Earnings Per Share (EPS) (after Extraordinary items) of Rs. 10/- (not to be annualized)					
	a) Basic	0.02	0.02	0.00	0.06	-0.01
	b) Diluted	0.02	0.02	0.00	0.06	-0.01
<b>Notes:</b>						
1	The above results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today					
2	The Segment-wise details are not applicable to the company as company has no segments.					
3	The results are Ind-AS compliant however, the previous years figures are not subject to limit review or audit. However, the management has exercised necessary due diligence to ensure that the Financial Results provide a true and fair view of its affairs.					
4	Previous Period's figures have been reclassified/regrouped, where ever necessary.					

Date : May 26, 2017  
Place: Mumbai

  
 Abha Kapoor  
 Director (Finance) & CFO

**RUBRA MEDICAMENTS LIMITED**

**STATEMENT OF ASSETS AND LIABILITIES**

(Rs. In Lakhs)

A	EQUITY AND LIABILITIES		As on March 31, 2017 Audited	As on March 31, 2016 Audited
<b>1</b>	<b>Shareholders Funds</b>			
	(a)	Share Capital	546.83	546.83
	(b)	Reserves and Surplus	(505.03)	(508.43)
	(c)	Money received against share warrants		-
		<b>Sub-total - Shareholders' funds</b>	<b>41.80</b>	<b>38.40</b>
<b>2</b>	<b>Share application money pending allotment</b>		-	-
<b>3</b>	<b>Minority interest</b>		-	-
<b>4</b>	<b>Non-current liabilities</b>			
	(a)	Long-term borrowings	-	-
	(b)	Deferred tax liabilities (net)	7.47	7.46
	(c)	Other long-term liabilities	-	-
	(d)	Long-term provisions	-	-
		<b>Sub-total - Non-current liabilities</b>	<b>7.47</b>	<b>7.46</b>
<b>5</b>	<b>Current liabilities</b>			
	(a)	Short-term borrowings	-	-
	(b)	Trade payables	3.32	-
	(c)	Other current liabilities	-	-
	(d)	Short-term provisions	0.29	-
		<b>Sub-total - Current liabilities</b>	<b>3.61</b>	-
		<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>52.88</b>	<b>45.86</b>
<b>B</b>	<b>ASSETS</b>			
<b>1</b>	<b>Non-current assets</b>			
	(a)	Fixed assets	0.08	-
	(b)	Goodwill on consolidation	-	-
	(c)	Non-current investments	-	-
	(d)	Deferred tax assets (net)	-	-
	(e)	Long-term loans and advances	33.79	32.82
	(f)	Other non-current assets	1.69	1.69
		<b>Sub-total - Non-current assets</b>	<b>35.56</b>	<b>34.51</b>
<b>2</b>	<b>Current Assets</b>			
	(a)	Current investments	-	-
	(b)	Inventories	-	-
	(c)	Trade receivables	1.77	1.77
	(d)	Cash and cash equivalents	15.55	9.58
	(e)	Short-term loans and advances	-	-
	(f)	Other current assets	-	-
		<b>Sub-total - Current assets</b>	<b>17.32</b>	<b>11.36</b>
		<b>TOTAL - ASSETS</b>	<b>52.88</b>	<b>45.86</b>

